Immuneering Corp Return On Asset vs. Revenue
| IMRX Stock | USD 1.60 0.06 3.90% |
For Immuneering Corp profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immuneering Corp to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immuneering Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immuneering Corp's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immuneering Corp over time as well as its relative position and ranking within its peers.
Immuneering |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immuneering Corp. If investors know Immuneering will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immuneering Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immuneering Corp is measured differently than its book value, which is the value of Immuneering that is recorded on the company's balance sheet. Investors also form their own opinion of Immuneering Corp's value that differs from its market value or its book value, called intrinsic value, which is Immuneering Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immuneering Corp's market value can be influenced by many factors that don't directly affect Immuneering Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immuneering Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immuneering Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immuneering Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immuneering Corp Revenue vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immuneering Corp's current stock value. Our valuation model uses many indicators to compare Immuneering Corp value to that of its competitors to determine the firm's financial worth. Immuneering Corp is rated below average in return on asset category among its peers. It is rated below average in revenue category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immuneering Corp's earnings, one of the primary drivers of an investment's value.Immuneering Revenue vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Immuneering Corp |
| = | -0.42 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Immuneering Corp |
| = | 455 |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Immuneering Revenue vs Competition
Immuneering Corp is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 193.27 Million. Immuneering Corp adds roughly 455 in revenue claiming only tiny portion of equities under Health Care industry.
Immuneering Corp Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immuneering Corp, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immuneering Corp will eventually generate negative long term returns. The profitability progress is the general direction of Immuneering Corp's change in net profit over the period of time. It can combine multiple indicators of Immuneering Corp, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. Immuneering Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
Immuneering Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immuneering Corp. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immuneering Corp position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immuneering Corp's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Immuneering Corp without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Use Investing Themes to Complement your Immuneering Corp position
In addition to having Immuneering Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run RUB Crypto Assets Thematic Idea Now
RUB Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in Russian Ruble. The RUB Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize RUB Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.